Zusammenfassung
Glucocorticoide werden in der Nebennierenrinde produziert. In den 1950er-Jahren wurden die immunsuppressiven und antientzündlichen Wirkungen der Glucocorticoide vermehrt therapeutisch genutzt und dabei auch das Potenzial schwerer unerwünschter Wirkungen zunehmend erkannt. Bis heute sind Glucocorticoide aus der Therapie immunvermittelter Erkrankungen einschließlich der Transplantationsmedizin nicht wegzudenken. In diesem Kapitel werden die Wirkmechanismen, die Pharmakokinetik und der praktische Einsatz der Glucocorticoide bei rheumatischen Erkrankungen beschrieben.
Similar content being viewed by others
Literatur
Batu ED (2019) Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int 39:13–27
Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63:465–482
Bloom BJ, Alario AJ, Miller LC (2011) Intra-articular corticosteroid therapy for juvenile idiopathic arthritis: report of an experiential cohort and literature review. Rheumatol Int 31:749–756
Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H (2011) Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 63:1–9
Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233–247
Deng J, Chalhoub N, Sherwin C, Caifeng L, Brunner HI (2019) Gucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 49:251–259
Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, Ganser G, Heiligenhaus A, Horneff G, Illhardt A, Kopp I, Krauspe R, Markus B, Michels H, Schneider M, Singendonk W, Sitter H, Spamer M, Wagner N, Niehues T (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193
Evans CH, Kraus VB, Setton LA (2014) Progress in intra-articular therapy. Nat Rev Rheumatol 10(1):11–22
Freier D, Strehl C, Buttgereit F (2019) CME-Fortbildung: Orale Glukokortikoide. Z Rheumatol 78:775–788
Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, Foeldvari I, Föll D, Frosch M, Ganser G et al (2019) Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 49:43–55
Ilowite NT, Laxer RM (2011) Pharmacology and drug therapy. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Hrsg) Textbook of pediatric rheumatology. Saunders-Elsevier, Philadelphia, S 71–126
Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K et al (2017) Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. Pediatr Rheumatol Online J 15(1):23
Lanni S, Bertamino M, Consolaro A, Pistorio A, Magni-Manzoni S, Galasso R, Lattanzi B, Calvo-Aranda E, Martini A, Ravelli A (2011) Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with Juvenile idiopathic arthritis. Rheumatology (Oxford) 50(9):1627–1634
Michels H (2000) What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? Z Rheumatol 59(Suppl 2):II/127–II/130
Michels H (2005) Juvenile idiopathische Arthritis – wann brauchen wir Glucocorticoide? Akt Rheumatol 30:183–186
Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT et al (2013) 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Care Res 65(10):1551–1563
Ringold S, Weiss PF, Colbert RA, Dewitt EM, Lee T et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular Juvenile idiopathic arthritis. Arthritis Care Res 66(7):1063–1072
Schimmer BP, Parker KL (2001) Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE (Hrsg) Goodman & Gilman’s the pharmacological basis of therapeutics, 10. Aufl. McGraw-Hill, New York, S 1663–1666
Stoeber E (1976) Corticosteroid treatment of juvenile chronic polyarthritis over 22 years. Eur J Pediatr 121:141–147
Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P (2004) Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 43:1288–1291
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Niehues, T., Wagner, N. (2021). Glucocorticoide in der pädiatrischen Rheumatologie. In: Wagner, N., Dannecker, G., Kallinich, T. (eds) Pädiatrische Rheumatologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60411-3_15-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-60411-3_15-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60411-3
Online ISBN: 978-3-662-60411-3
eBook Packages: Springer Referenz Medizin